Journal
EUROPEAN UROLOGY
Volume 76, Issue 3, Pages 340-351Publisher
ELSEVIER
DOI: 10.1016/j.eururo.2019.02.033
Keywords
Prostate cancer; Prostate Imaging Reporting and Data System Version 2; Prostate Imaging Reporting and Data System Version 2.1
Categories
Funding
- GlaxoSmithKline
- Profound Medical
- Siemens Healthineers
- Royalties
- NIH [P41 EB 015898, R25 NCI CA089017]
- NATIONAL CANCER INSTITUTE [ZIABC010655] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) was developed with a consensus-based process using a combination of published data, and expert observations and opinions. In the short time since its release, numerous studies have validated the value of PI-RADS v2 but, as expected, have also identified a number of ambiguities and limitations, some of which have been documented in the literature with potential solutions offered. To address these issues, the PI-RADS Steering Committee, again using a consensus-based process, has recommended several modifications to PI-RADS v2, maintaining the framework of assigning scores to individual sequences and using these scores to derive an overall assessment category. This updated version, described in this article, is termed PI-RADS v2.1. It is anticipated that the adoption of these PI-RADS v2.1 modifications will improve inter-reader variability and simplify PI-RADS assessment of prostate magnetic resonance imaging even further. Research on the value and limitations on all components of PI-RADS v2.1 is strongly encouraged. Published by Elsevier B.V. on behalf of European Association of Urology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available